TAK-165|Mubritinib is an EGFR2 (HER2) inhibitor that underwent clinical trials, showing some promise as an anticancer chemotherapeutic in the treatment of bladder, kidney, and prostate cancer, but was not pursued further.|C25H23F3N4O2|468.47||Ambient|